Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Assets Average (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Assets Average for 15 consecutive years, with $5.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Assets Average rose 33.27% to $5.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.2 million, a 33.27% increase, with the full-year FY2024 number at $6.2 million, down 51.02% from a year prior.
  • Assets Average was $5.2 million for Q3 2025 at NovaBay Pharmaceuticals, down from $8.4 million in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $24.4 million in Q1 2022 to a low of $3.6 million in Q4 2024.
  • A 5-year average of $12.9 million and a median of $13.8 million in 2021 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: tumbled 72.97% in 2024, then soared 80.81% in 2025.
  • NovaBay Pharmaceuticals' Assets Average stood at $18.1 million in 2021, then increased by 7.06% to $19.4 million in 2022, then tumbled by 43.56% to $10.9 million in 2023, then crashed by 66.65% to $3.6 million in 2024, then surged by 42.44% to $5.2 million in 2025.
  • Per Business Quant, the three most recent readings for NBY's Assets Average are $5.2 million (Q3 2025), $8.4 million (Q2 2025), and $6.6 million (Q1 2025).